SuperworthSkinHealth Systems SKIN
- Market cap
- $70.8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.2×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $290M
- −6% on a year ago
- Net margin
- −9.8%
- Free cash flow yield
- 29.9%
SkinHealth Systems trades at 0.2× sales. Its trailing earnings are negative, so it has no PE. Revenue was $290M over the last twelve months, down 6% on a year earlier with a −10% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $97.4M+10% | $96.8M−1% | $81.4M−6% | $90.6M−23% | $78.8M−19% | $83.5M−14% | $69.6M−15% | $78.2M−14% | $70.7M−10% | $82.4M−1% | $64.9M−7% | $72.1M−8% | |
| Cost of revenue | $110M+301% | $51.1M+62% | $33M+3% | $49.7M+0% | $38.2M−65% | $31.1M−39% | $21M−36% | $29.1M−41% | $25M−34% | $29.3M−6% | $20.5M−3% | $22.8M−22% |
| Gross profit | −$12.6M | $45.7M−31% | $48.4M−11% | $40.9M−40% | $40.6M | $52.3M+15% | $48.6M+1% | $49.1M+20% | $45.6M+12% | $53M+1% | $44.4M−9% | $49.3M+1% |
| R&D | $1.8M−15% | $3M+111% | $2.8M+20% | $1.2M−60% | $1.1M−40% | $1.2M−60% | $998K−64% | $1.3M+8% | $1.7M+53% | $1.7M+38% | $1.1M+10% | $1.4M+13% |
| SG&A | $67.7M+7% | $61M−10% | $62.5M−10% | $61.9M−21% | $61.1M−10% | $58.3M−5% | $59.6M−5% | $50.6M−18% | $50.2M−18% | $51.2M−12% | $45.1M−24% | $44.4M−12% |
| −$82.1M+1786% | −$18.4M+650% | −$17M−2% | −$22.1M+68% | −$21.5M−74% | −$7.2M−61% | −$12M−29% | −$2.7M−88% | −$6.2M−71% | $162K | −$1.8M−85% | $3.6M | |
| Interest expense | $3.4M+2% | $3.4M−1% | $3M−11% | $2.5M−29% | $2.5M−28% | $2.5M−27% | $2.5M−18% | $4.1M+69% | $6.3M+156% | $6.4M+159% | $6.3M+154% | $6.3M+52% |
| Pre-tax income | −$70.3M+7698% | −$8.8M | −$1.3M−94% | −$151K | −$16.3M−77% | −$11.7M+33% | −$9.2M+588% | $18.7M | −$10.6M−35% | −$4.8M−59% | −$6.8M−26% | −$1.5M |
| $3.5M | $603K | −$659K−82% | −$353K−84% | $1.9M−44% | −$1.4M | $892K | −$993K+181% | $386K−80% | $3.3M | −$184K | $1.2M | |
| Net income | −$73.8M+91033% | −$9.4M | −$679K−97% | $202K−94% | −$18.3M−75% | −$10.3M+10% | −$10.1M+1387% | $19.7M+9658% | −$11M−40% | −$8.1M−22% | −$6.6M−34% | −$2.7M |
| −$11.20+1767% | −$1.40 | −$2.00−33% | −$2.00 | −$3.00−73% | −$1.60+14% | −$1.60−20% | $0.60 | −$1.80−40% | −$1.20−25% | −$1.00−38% | −$0.40 | |
| 6.6M−12% | 6.4M−7% | 7.2M+9% | 7.1M+7% | 6.2M−7% | 6.2M−3% | 6.3M−13% | 7M−1% | 6.3M+2% | 6.4M+2% | 6.6M+5% | 6.5M−8% |
Revenue: Q1 FY20: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY20: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY20: 6 months less the 3 months printed beside them.
R&D: Q1 FY20: 6 months less the 3 months printed beside them.
SG&A: Q1 FY20: 6 months less the 3 months printed beside them.
Operating income: Q1 FY20: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY20: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY20: 6 months less the 3 months printed beside them.
Income tax: Q1 FY20: 6 months less the 3 months printed beside them.
Net income: Q1 FY20: 6 months less the 3 months printed beside them.
EPS, diluted: 7 periods, Q1 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY20: share-days: the 6-month average less the second quarter's. Q4 FY20: share-days: the 6-month average less the 3-month, weighted by days. 4 periods, Q4 FY21 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY22: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest SkinHealth Systems' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SKINSkinHealth Systems | $70.8M | n/m | n/a | 0.2× | −6% | −9.8% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| MOVMovado | $701.9M | 17.5× | 13.3× | 1.0× | +5% | 6.0% | |
| Peer median | $257M | 19.7× | 18.7× | 1.6× | +5% | 6.9% |
More on SkinHealth Systems
Each number over time
- PE ratio
- Price to sales ratio
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #1of 199Healthcare stocks with the highest free cash flow yield
- #1of 45Medical instruments and supplies stocks with the highest free cash flow yield
- #5of 116Medical instruments and supplies stocks with the lowest price to sales ratio
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .